Digital ctDNA - Ny AI-basert biomarkør for å tilpasse behandling ved tarmkreft

Offentlig prosjektsammendrag

A lack of reliable and affordable biomarkers to personalize treatment remains a major unsolved challenge in colorectal cancer (CRC), the third most common and second most deadly cancer with one million patients affected by localized stage II and III. Surgery is the standard of care in this indication, often followed by adjuvant chemotherapy (ACT). However, most patients are cured by surgery alone and ACT provides no benefit to the majority of patients, only exposing them to devastating short- and long-term side effects. There is therefore a need for better biomarkers to guide ACT treatment decisions. The current project aims to solve this unmet medical need by developing new treatment decision tools utilizing state-of-the-art AI-based digital biomarker technologies and DNA-based tumor detection approaches. The project will establish a new standard in precision oncology; improving patient outcomes, lowering healthcare costs and resource use, and addressing a critical unmet medical need